About Ubiquitin carboxyl-terminal hydrolase 17-like protein 24
Ubiquitin carboxyl-terminal hydrolase 17-like protein 24 (USP17L24) is a protein
from Homo sapiens identified by UniProt accession
Q0WX57, 530 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
Disease associations (25)
Diseases linked to this target (Open Targets).
- urate measurement · score 0.04
- immunodeficiency 19 · score 0.04
- combined immunodeficiency with skin granulomas · score 0.03
- immunodeficiency 73c with defective neutrophil chemotaxis and hypogammaglobulinemia · score 0.03
- severe combined immunodeficiency due to IKK2 deficiency · score 0.03
- ring chromosome Y · score 0.03
- X-Linked Combined Immunodeficiency Diseases · score 0.03
- severe combined immunodeficiency due to LAT deficiency · score 0.03
- obesity due to congenital leptin deficiency · score 0.03
- immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Experimental structures are not indexed in MolForge yet —
search RCSB PDB for Q0WX57.
Amino-acid sequence (530 residues)
MEDDSLYLRG EWQFNHFSKL TSSRPDAAFA EIQRTSLPEK SPLSCETRVD LCDDLAPVAR QLAPREKLPL SSRRPAAVGA GLQNMGNTCY VNASLQCLTY TPPLANYMLS REHSQTCHRH KGCMLCTMQA HITRALHNPG HVIQPSQALA AGFHRGKQED AHEFLMFTVD AMKKACLPGH KQVDHHSKDT TLIHQIFGGY WRSQIKCLHC HGISDTFDPY LDIALDIQAA QSVQQALEQL VKPEELNGEN AYHCGVCLQR APASKTLTLH TSAKVLILVL KRFSDVTGNK IAKNVQYPEC LDMQPYMSQP NTGPLVYVLY AVLVHAGWSC HNGHYFSYVK AQEGQWYKMD DAEVTASSIT SVLSQQAYVL FYIQKSEWER HSESVSRGRE PRALGAEDTD RRATQGELKR DHPCLQAPEL DEHLVERATQ ESTLDHWKFL QEQNKTKPEF NVRKVEGTLP PDVLVIHQSK YKCGMKNHHP EQQSSLLNLS SSTPTHQESM NTGTLASLRG RARRSKGKNK HSKRALLVCQ
Explore Ubiquitin carboxyl-terminal hydrolase 17-like protein 24 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets